28. April 2020 - Ca2+ channel assays
"Validation and optimization of automated patch clamp voltage-gated Ca2+ channel assays"
Date: 28. April 2020
Time: 4:00 PM CET / 10:00 AM EST
Speakers:
Dr. Marc Rogers (Chief Scientific Officer, Metrion Biosciences)
Dr. András Horváth (Application Scientist, Nanion Technologies)
Abstract:
Marc will outline the development, optimization and validation of a range of voltage-gated Ca2+ channel assays on the Patchliner automated patch clamp platform that were subsequently used in an 8 year drug discovery collaboration between Metrion Biosciences and a german pharma company.
The project was successful in identifying several lead series of selective,state-dependent inhibitors of Cav2.2 N-type channels for use as novel, non-opioid analgesic.This required the creation of biophysical screening assays to identify the potency of small molecules against the resting and inactivated state of the human neuronal Ca2+ channels Cav2.1(P/Q type), Cav2.2 and Cav3.2 (T-type), some of which are notoriously difficult in terms of expression levels and current rundown.
Register for our monthly Newsletter and we will keep you informed.
SyncroPatch 384PE (a predecessor model of SyncroPatch 384i), 
Patchliner, 
Port-a-Patch Webinar
CardioExcyte 96, 
FLEXcyte 96, 
Orbit mini and 
Orbit 16
This webinar covers the use of the lipid bilayer platforms from Nanion: the Orbit16 and the Orbit mini for characterization of membrane proteins like ion channels, bacterial porins and biological nanopores. Both bilayer systems support high quality low noise recordings, but differ in throughput capabilities and experimental features. The Orbit16, introduced in 2012 is a device for efficient formation of 16 lipid bilayers simultaneously, allowing for parallel bilayer-reconstitution of ion channels and nanopores.
SURFE²R 96SE and 
SURFE²R N1